Defense Health Board (DHB) Meeting, 62223 [07-5455]

Download as PDF pwalker on PROD1PC71 with NOTICES Federal Register / Vol. 72, No. 212 / Friday, November 2, 2007 / Notices necessary to implement an agreement with one or more NAFTA country on such a modification. See section 202(q) of the NAFTA Implementation Act. On October 29, 2007, the Chairman of CITA received a request from Monterey Mills, alleging that certain acrylic staple fibers, not carded, combed or otherwise processed for spinning, classified under subheading 5503.30 of the Harmonized Tariff Schedule of the United States (HTSUS), cannot be supplied by the domestic industry in commercial quantities in a timely manner and requesting that CITA consider whether the North American Free Trade Agreement (NAFTA) rule of origin for knit pile fabrics, classified under HTSUS subheading 6001.10, should be modified to allow the use of non-North American acrylic staple fiber. CITA is soliciting public comments regarding this request, particularly with respect to whether the acrylic staple fiber described above can be supplied by the domestic industry in commercial quantities in a timely manner. Comments must be received no later than December 3, 2007. Interested persons are invited to submit six copies of such comments or information to the Chairman, Committee for the Implementation of Textile Agreements, Room 3100, U.S. Department of Commerce, 14th and Constitution Avenue, N.W., Washington, DC 20230. If a comment alleges that these acrylic staple fibers can be supplied by the domestic industry in commercial quantities in a timely manner, CITA will closely review any supporting documentation, such as a signed statement by a manufacturer stating that it produces fiber that is the subject of the request, including the quantities that can be supplied and the time necessary to fill an order, as well as any relevant information regarding past production. CITA will protect any business confidential information that is marked business confidential from disclosure to the full extent permitted by law. CITA will make available to the public nonconfidential versions of the request and non-confidential versions of any public comments received with respect to a request in room 3100 in the Herbert Hoover Building, 14th and Constitution Avenue, N.W., Washington, DC 20230. Persons submitting comments on a request are encouraged to include a nonconfidential version and a nonconfidential summary. R. Matthew Priest, Chairman, Committee for the Implementation of Textile Agreements. [FR Doc. E7–21627 Filed 11–1–07; 8:45 am] BILLING CODE 3510–DS VerDate Aug<31>2005 16:46 Nov 01, 2007 Jkt 214001 DEPARTMENT OF DEFENSE Office of the Secretary Defense Health Board (DHB) Meeting Department of Defense. Notice of meeting. AGENCY: ACTION: SUMMARY: Pursuant to the Federal Advisory Committee Act of 1972 (5 U.S.C. Appendix as amended), the Sunshine in the Government Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR 102–3.150, and in accordance with section 10(a)(2) of Public Law, the following meeting is announced: Name of Committee: Defense Health Board (DHB). Dates: December 11 and 12, 2007. Times: December 11, 2007. 8 a.m.–12:15 p.m. (Open Session). 1:30 p.m.–4:15 p.m. (Open Session). December 12, 2007. 8:30 a.m.–12 p.m. (Open Session). Place of Meeting: Sheraton Crystal City, 1800 Jefferson Davis Highway, Arlington, Virginia 22202. Purpose of the Meeting: The purpose of the meeting is to address and deliberate pending and new Board issues and provide briefings for Board members on topics related to ongoing Board business. Agenda: The Board will deliberate the findings and recommendations of the Task Force on the Future of Military Health Care and receive an update on the Department’s efforts to reengineer the Disability Evaluation Program. The Board will receive reports from the Psychological Health and Traumatic Brain Injury External Advisory Subcommittees. The Board will also deliberate recommendations regarding Emergency Blood Transfusion Safety and discuss DoD’s convalescent plasma treatment guidelines development. Pandemic influenza preparedness and Chlamydia infection control will also be discussed. On December 12, 2007, the board will hold a short preparatory session before the beginning of the open meeting and an administrative session after the open meeting is adjourned. The preparatory and administrative sessions are closed to the public. Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102–3.140 through 102–3.165 and subject availability of space, the Defense Health Board meeting from 8 a.m. to 4:15 p.m. on December 11, 2007 and from 8:30 a.m. to 12 p.m. on December 12, 2007 is open to the public. Any member of the public wishing to provide input to the Defense Health Board should submit a written statement in accordance with PO 00000 Frm 00020 Fmt 4703 Sfmt 4703 62223 41 CFR 102–3.140(C) and section 10(a)(3) of the Federal Advisory Committee Act, and the procedures described in this notice. Written statement should be not longer than two type-written pages and must address the following detail: The issue, discussion, and a recommended course of action. Supporting documentation may also be included as needed to establish the appropriate historical context and to provide any necessary background information. Individuls desiring to submit a written statement may do so through the Board’s Designated Federal Officer at the address detailed below at any point. However, if the written statement is not received at least 10 calendar days prior to the meeting, which is subject to this notice, then it may not be provided to or considered by the Defense Health Board until the next open meeting. The Designated Federal Officer will review all timely submissions with the Defense Health Board Chairperson, and ensure they are provided to members of the Defense Health Board before the meeting that is subject to this notice. After reviewing the written comments, the Chairperson and the Designated Federal Officer may choose to invite the submitter of the comments to orally present their issue during an open portion of this meeting or at a future meeting. The Designated Federal Officer, in consultation with the Defense Health Board Chairperson, may, if desired, allot a specific amount of time for members of the public to present their issues for review and discussion by the Defense Health Board. FOR FURTHER INFORMATION CONTACT: Colonel Roger L. Gibson, Executive Secretary, Defense Health Board, Five Skyline Place, 5111 Leesburg Pike, Room 810, Falls Church, Virginia 22041–3206, (703) 681–3279, Ext 123, Fax: (703–681–3321, (roger.gibson@ha.ods.mil). Additional information, agenda updates, and meeting registration are available online at the Defense Health Board Web site, https://www.ha.osd.mil/dhb. The public is encouraged to register for the meeting. Written statements may be mailed to the above address, e-mailed to dhb@ha.osd.mil of faxed to (703) 681– 3321. Dated: October 29, 2007. L.M. Bynum, Liaison Officer, Department of Defense. [FR Doc. 07–5455 Filed 11–1–07; 8:45 am] BILLING CODE 5501–06–M E:\FR\FM\02NON1.SGM 02NON1

Agencies

[Federal Register Volume 72, Number 212 (Friday, November 2, 2007)]
[Notices]
[Page 62223]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-5455]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Defense Health Board (DHB) Meeting

AGENCY: Department of Defense.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Pursuant to the Federal Advisory Committee Act of 1972 (5 
U.S.C. Appendix as amended), the Sunshine in the Government Act of 1976 
(5 U.S.C. 552b, as amended), and 41 CFR 102-3.150, and in accordance 
with section 10(a)(2) of Public Law, the following meeting is 
announced:
    Name of Committee: Defense Health Board (DHB).
    Dates: December 11 and 12, 2007.

Times: December 11, 2007.
    8 a.m.-12:15 p.m. (Open Session).
    1:30 p.m.-4:15 p.m. (Open Session).
December 12, 2007.
    8:30 a.m.-12 p.m. (Open Session).

    Place of Meeting: Sheraton Crystal City, 1800 Jefferson Davis 
Highway, Arlington, Virginia 22202.
    Purpose of the Meeting: The purpose of the meeting is to address 
and deliberate pending and new Board issues and provide briefings for 
Board members on topics related to ongoing Board business.
    Agenda: The Board will deliberate the findings and recommendations 
of the Task Force on the Future of Military Health Care and receive an 
update on the Department's efforts to reengineer the Disability 
Evaluation Program. The Board will receive reports from the 
Psychological Health and Traumatic Brain Injury External Advisory 
Subcommittees. The Board will also deliberate recommendations regarding 
Emergency Blood Transfusion Safety and discuss DoD's convalescent 
plasma treatment guidelines development. Pandemic influenza 
preparedness and Chlamydia infection control will also be discussed.
    On December 12, 2007, the board will hold a short preparatory 
session before the beginning of the open meeting and an administrative 
session after the open meeting is adjourned. The preparatory and 
administrative sessions are closed to the public.
    Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.140 through 
102-3.165 and subject availability of space, the Defense Health Board 
meeting from 8 a.m. to 4:15 p.m. on December 11, 2007 and from 8:30 
a.m. to 12 p.m. on December 12, 2007 is open to the public. Any member 
of the public wishing to provide input to the Defense Health Board 
should submit a written statement in accordance with 41 CFR 102-
3.140(C) and section 10(a)(3) of the Federal Advisory Committee Act, 
and the procedures described in this notice. Written statement should 
be not longer than two type-written pages and must address the 
following detail: The issue, discussion, and a recommended course of 
action. Supporting documentation may also be included as needed to 
establish the appropriate historical context and to provide any 
necessary background information.
    Individuls desiring to submit a written statement may do so through 
the Board's Designated Federal Officer at the address detailed below at 
any point. However, if the written statement is not received at least 
10 calendar days prior to the meeting, which is subject to this notice, 
then it may not be provided to or considered by the Defense Health 
Board until the next open meeting.
    The Designated Federal Officer will review all timely submissions 
with the Defense Health Board Chairperson, and ensure they are provided 
to members of the Defense Health Board before the meeting that is 
subject to this notice. After reviewing the written comments, the 
Chairperson and the Designated Federal Officer may choose to invite the 
submitter of the comments to orally present their issue during an open 
portion of this meeting or at a future meeting.
    The Designated Federal Officer, in consultation with the Defense 
Health Board Chairperson, may, if desired, allot a specific amount of 
time for members of the public to present their issues for review and 
discussion by the Defense Health Board.

FOR FURTHER INFORMATION CONTACT: Colonel Roger L. Gibson, Executive 
Secretary, Defense Health Board, Five Skyline Place, 5111 Leesburg 
Pike, Room 810, Falls Church, Virginia 22041-3206, (703) 681-3279, Ext 
123, Fax: (703-681-3321, (roger.gibson@ha.ods.mil). Additional 
information, agenda updates, and meeting registration are available 
online at the Defense Health Board Web site, https://www.ha.osd.mil/dhb. 
The public is encouraged to register for the meeting. Written 
statements may be mailed to the above address, e-mailed to 
dhb@ha.osd.mil of faxed to (703) 681-3321.

    Dated: October 29, 2007.
L.M. Bynum,
Liaison Officer, Department of Defense.
[FR Doc. 07-5455 Filed 11-1-07; 8:45 am]
BILLING CODE 5501-06-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.